Each year, there are more than 20,000 influenza associated deaths during influenza virus epidemics. There is an increase in hospital admission for patients with pneumonia, exacerbation of chronic obstructive pulmonary disease, croup, and congestive heart failure, and an increase in school and industrial absenteeism. Yet only 30% of the high-risk target population receives influenza vaccination annually. Health care providers and patients are reluctant to use vaccine despite its generally excellent record of safety and its approximately 70% efficacy when vaccine and epidemic strains match. The continuing change in antigenic composition of the influenza A virus and waning immunity requires annual vaccination. Vaccine composition and target groups are reviewed. Strategies for improving vaccine usage are emphasized.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Dispersal of influenza virus populations within the respiratory tract shapes their evolutionary potential.
Proc Natl Acad Sci U S A
January 2025
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
Viral infections are characterized by dispersal from an initial site to secondary locations within the host. How the resultant spatial heterogeneity shapes within-host genetic diversity and viral evolutionary pathways is poorly understood. Here, we show that virus dispersal within and between the nasal cavity and trachea maintains diversity and is therefore conducive to adaptive evolution, whereas dispersal to the lungs gives rise to population heterogeneity.
View Article and Find Full Text PDFA gram-positive enhancer matrix particles vaccine displaying swine influenza virus hemagglutinin protects mice against lethal H1N1 viral challenge.
Front Immunol
January 2025
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Introduction: Animal influenza viruses pose a danger to the general public. Eurasian avian-like H1N1 (EA H1N1) viruses have recently infected humans in several different countries and are often found in pigs in China, indicating that they have the potential to cause a pandemic. Therefore, there is an urgent need to develop a potent vaccine against EA H1N1.
View Article and Find Full Text PDFThe accuracy of forecasted hospital admission for respiratory tract infections in children aged 0-5 years for 2017/2023.
Front Pediatr
January 2025
Cluster for Health Services Research, Norwegian Institute of Public Health, Oslo, Norway.
Aim: Healthcare services are in need of tools that can help to ensure a sufficient capacity in periods with high prevalence of respiratory tract infections (RTIs). During the COVID-19 pandemic, we forecasted the number of hospital admissions for RTIs among children aged 0-5 years. Now, in 2024, we aim to examine the accuracy and usefulness of our forecast models.
View Article and Find Full Text PDFLung-specific CRBN knockout attenuates influenza a virus-induced acute lung injury in mice: a potential therapeutic approach.
BMC Infect Dis
January 2025
State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China.
Influenza-related acute lung injury is a life-threatening condition primarily caused by uncontrolled replication of the influenza virus and intense proinflammatory responses. Cereblon (CRBN) is a protein known for its role in the ubiquitin-proteasome system and as a target of the drug thalidomide. However, the function of CRBN in influenza virus infection remains poorly understood.
View Article and Find Full Text PDFPeptide fibrils as a vaccine: Proof of concept.
J Immunol Methods
January 2025
Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, St. Petersburg 194064, Russia; Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Ulitsa Prof. Popova, St. Petersburg 197376, Russia; Institute of Experimental Medicine, 12 Ulitsa Akademika Pavlova, St. Petersburg 197376, Russia.
Background: Rapid vaccine platforms development is crucial for responding to epidemics and pandemics of emerging infectious diseases, such as Ebola. This study explores the potential of peptide vaccines that self-organize into amyloid-like fibrils, aiming to enhance immunogenicity while considering safety and cross-reactivity.
Methods: We synthesized two peptides, G33 and G31, corresponding to a segment of the Ebola virus GP2 protein, with G33 known to form amyloid-like fibrils.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!